Literature DB >> 26469881

Imaging Patterns and Outcome of Posterior Reversible Encephalopathy Syndrome During Childhood Cancer Treatment.

Raja B Khan1, Zsila S Sadighi1, Jennifer Zabrowski1, Amar Gajjar2, Sima Jeha3.   

Abstract

BACKGROUND: Diagnosis of posterior reversible encephalopathy syndrome (PRES) requires presence of headache, seizures, impaired vision, or altered mentation accompanied by specific imaging findings. We aimed to study long-term clinical and radiologic outcome of PRES in children with cancer to augment limited available data. PROCEDURE: Retrospective review of children with cancer who were diagnosed with PRES.
RESULTS: We identified PRES in 21 males and 16 females among 5,217 children treated during the study period. Median time from cancer diagnosis to PRES was 6.6 months in 25 leukemia (1.6%), five brain tumor (0.3%), and seven other solid tumor (0.4%) patients; P = <0.0001 for leukemia versus all other tumors. Symptoms included seizures (97%), headaches (40%), altered mentation (68%), and vision impairment (27%). Hypertension was seen in 97%, and steroids use was seen in 78%. Headaches, visual disturbance, and mental status resolved within a median of <3 days, whereas epilepsy developed in 19%. T2 hyperintense signal was present in 100% of occipital, 47% of temporal, 75% of parietal, and 55% of frontal lobes, as well as 22% of cerebellum and 5% of basal ganglia. Follow-up magnetic resonance imaging (MRI) in 34 patients showed partial or complete T2 resolution in 79%, development of laminar necrosis in five, microhemorrhages in six, and focal atrophy in three.
CONCLUSION: PRES in children is more common in hematological malignancy compared with other tumors and is associated with hypertension and steroid use. Seizure is the most common acute manifestation. Most MRI changes resolve, but persistent imaging abnormality and epilepsy may develop in a significant minority.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  PRES; cancer; childhood; outcome

Mesh:

Substances:

Year:  2015        PMID: 26469881      PMCID: PMC4724342          DOI: 10.1002/pbc.25790

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  13 in total

Review 1.  Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.

Authors:  Zaw W Myint; Jeremy M Sen; Nicole L Watts; Thomas J Druzgal; Barnett R Nathan; Melanie D Ward; James E Boyer; Paula M Fracasso
Journal:  Clin Colorectal Cancer       Date:  2013-12-27       Impact factor: 4.481

2.  MRI Findings in Childhood PRES: What is Different than the Adults?

Authors:  F Y Donmez; P Guleryuz; M Agildere
Journal:  Clin Neuroradiol       Date:  2014-10-08       Impact factor: 3.649

3.  Neuropathology of a fatal case of posterior reversible encephalopathy syndrome.

Authors:  John N Kheir; Michael W Lawlor; Edward S Ahn; Leslie Lehmann; James J Riviello; V Michelle Silvera; Michael McManus; Rebecca D Folkerth
Journal:  Pediatr Dev Pathol       Date:  2010-02-16

4.  Life-threatening complications of posterior reversible encephalopathy syndrome in children.

Authors:  Duccio M Cordelli; Riccardo Masetti; Emilia Ricci; Francesco Toni; Daniele Zama; Monica Maffei; Andrea Gentili; Antonia Parmeggiani; Andrea Pession; Emilio Franzoni
Journal:  Eur J Paediatr Neurol       Date:  2014-04-25       Impact factor: 3.140

5.  Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome.

Authors:  W S Bartynski; J F Boardman
Journal:  AJNR Am J Neuroradiol       Date:  2007-12-13       Impact factor: 3.825

6.  Tumor lysis syndrome as a risk factor for posterior reversible encephalopathy syndrome in children with hematological malignancies.

Authors:  Daisuke Suzuki; Ryoji Kobayashi; Akihiro Iguchi; Hirozumi Sano; Kenji Kishimoto; Kazue Yasuda; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2014-09-13       Impact factor: 2.490

Review 7.  Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects!

Authors:  Arushi Khurana; Constantin A Dasanu
Journal:  J Oncol Pharm Pract       Date:  2014-07-09       Impact factor: 1.809

8.  Posterior reversible encephalopathy syndrome in children: radiological and clinical findings - a retrospective analysis of a German tertiary care center.

Authors:  E Siebert; B Spors; G Bohner; M Endres; T G Liman
Journal:  Eur J Paediatr Neurol       Date:  2012-09-04       Impact factor: 3.140

9.  Clinical spectrum of reversible posterior leukoencephalopathy syndrome.

Authors:  Vivien H Lee; Eelco F M Wijdicks; Edward M Manno; Alejandro A Rabinstein
Journal:  Arch Neurol       Date:  2008-02

10.  Clinical and radiological spectrum of posterior reversible encephalopathy syndrome: does age make a difference?--A retrospective comparison between adult and pediatric patients.

Authors:  Eberhard Siebert; Georg Bohner; Matthias Endres; Thomas G Liman
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

View more
  13 in total

1.  Posterior reversible encephalopathy syndrome: characteristics, diagnostic accuracy, prognostic factors and long-term outcome in a paediatric population.

Authors:  Catarina Marques Duarte; Ana Sofia Vilardouro; Duarte Rebelo; Sofia Quintas; Francisco Abecasis
Journal:  Acta Neurol Belg       Date:  2021-10-24       Impact factor: 2.396

2.  Clinical features, predictors and outcome of posterior reversible encephalopathy syndrome (PRES) in children with hematolymphoid malignancies.

Authors:  Subramaniam Ramanathan; Vignesh Subramani; Seema Kembhavi; Maya Prasad; Nirmalya Roy Moulik; Chetan Dhamne; Gaurav Narula; Shripad Banavali
Journal:  Childs Nerv Syst       Date:  2022-05-25       Impact factor: 1.532

3.  Neurotoxicity including posterior reversible encephalopathy syndrome after initiation of calcineurin inhibitors in transplanted methylmalonic acidemia patients: Two case reports and review of the literature.

Authors:  Femke Molema; Monique Williams; Janneke Langendonk; Sarwa Darwish-Murad; Jacqueline van de Wetering; Ed Jacobs; Willem Onkenhout; Esther Brusse; Anke van der Eerden; Margreet Wagenmakers
Journal:  JIMD Rep       Date:  2020-01-22

4.  Posterior Reversible Encephalopathy Syndrome: Incidence and Clinical Characteristics in Children With Cancer.

Authors:  Katherine R Sommers; Jodi Skiles; Brian Leland; Courtney M Rowan
Journal:  J Pediatr Hematol Oncol       Date:  2022-03-01       Impact factor: 1.170

Review 5.  Posterior reversible encephalopathy syndrome.

Authors:  Marlene Fischer; Erich Schmutzhard
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

Review 6.  Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.

Authors:  Kjeld Schmiegelow; Klaus Müller; Signe Sloth Mogensen; Pernille Rudebeck Mogensen; Benjamin Ole Wolthers; Ulrik Kristoffer Stoltze; Ruta Tuckuviene; Thomas Frandsen
Journal:  F1000Res       Date:  2017-04-07

7.  Clinico-radiological Profile of Posterior Reversible Encephalopathy Syndrome and Its Associated Risk Factors in PICU: A Single-center Experience from a Tertiary Care Hospital in Bhubaneswar, Odisha.

Authors:  Chinmay K Behera; Mukesh K Jain; Reshmi Mishra; Pratap K Jena; Santosh K Dash; Ranjan K Sahoo
Journal:  Indian J Crit Care Med       Date:  2020-12

8.  Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size.

Authors:  Marady Hun; Min Xie; Zhou She; Amin S Abdirahman; Cuifang Li; Feifeng Wu; Senlin Luo; Phanna Han; Rithea Phorn; Pan Wu; Haiyan Luo; Keke Chen; Jidong Tian; Wuqing Wan; Chuan Wen
Journal:  Front Pediatr       Date:  2021-07-01       Impact factor: 3.418

9.  PRES in the course of hemato-oncological treatment in children.

Authors:  Katarzyna Musioł; Sylwia Waz; Michał Boroń; Magdalena Kwiatek; Magdalena Machnikowska-Sokołowska; Katarzyna Gruszczyńska; Grażyna Sobol-Milejska
Journal:  Childs Nerv Syst       Date:  2017-12-02       Impact factor: 1.475

10.  Posterior Reversible Encephalopathy Syndrome in Pediatric Cancer: Clinical and Radiologic Findings.

Authors:  Saadiya Javed Khan; Arjumand Ali Arshad; Mohammad Bilal Fayyaz; Islah Ud Din Mirza
Journal:  J Glob Oncol       Date:  2017-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.